Murae Organisor (542724)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• P/B of 0.97, trading below book value of ₹1.47 per share
• Low reported P/E of 2.96 and PEG of 0.00 on current earnings
• Piotroski F-Score of 7/9 suggests improving financial health signals
• Reported sales growth of 1,634% and profit growth of 1,000% show momentum
• Latest quarter is profitable with net profit of ₹7 crore

Concerns

• Latest quarter net profit of ₹7 crore exceeds sales of ₹4 crore, raising earnings-quality red flags
• ROE of 2.84% and ROCE of 4.20% show weak efficiency in deploying capital
• No dividend, no promoter holding data, and no debt/equity disclosure reduce transparency
• Stock has run from ₹0.19 to ₹1.43 in its 52-week range, so much of the recovery may already be priced in

AI Analysis

When I look at Murae Organisor, I first see a cheap-looking pharmaceutical micro-cap: price ₹1.43, market cap ₹102 crore, P/E 2.96, and P/B 0.97. That means the market is valuing the company slightly below its ₹1.47 per-share book value. A Piotroski F-Score of 7/9 adds some comfort on financial quality. Yet the arithmetic bothers me. The latest quarter reports sales of ₹4 crore and net profit of ₹7 crore. In Graham's world, profits should come from revenues; profit greater than turnover usually signals one-time gains, not operating strength. ROE of 2.84% and ROCE of 4.20% tell me the underlying business earns little on capital. The reported sales growth of 1,634% and profit growth of 1,000% look astonishing, but they start from a tiny base, so they tell me nothing about durability. A PEG of 0.00 is a red flag: the market appears to extrapolate this spike forever, while I assume mean-reversion. There is no dividend, promoter holding is N/A, and debt/equity is N/A. Missing data is not a minor omission; it is a reason to withhold trust. The stock is at the upper end of its 52-week range, from ₹0.19 to ₹1.43, so the market has already found the recovery. I cannot identify a durable moat in these numbers. This is not a fast grower or a stalwart; it is an asset play, and only if the book value is real and protectable. I would need more operating evidence, better return on equity, and cleaner profit quality before committing capital. Until then, this remains a watch-list name, not a Buffett holding.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer